Provided By GlobeNewswire
Last update: Jun 27, 2025
NEWTOWN, Pa., June 27, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, announced today a 1-for-50 reverse split of its Class A common stock, par value $0.001 (“common stock”), effective at 5:00 pm Eastern time on June 30, 2025. Beginning on July 1, 2025, the Company’s common stock will trade on The Nasdaq Capital Market on a split adjusted basis.
Read more at globenewswire.comNASDAQ:HSDT (9/5/2025, 5:25:30 PM)
5.94
-0.05 (-0.92%)
Find more stocks in the Stock Screener